FATE vs. LXEO, ITOS, ALVO, ADPT, REPL, TSHA, EDIT, CCCC, TCRX, and VYGR
Should you be buying Fate Therapeutics stock or one of its competitors? The main competitors of Fate Therapeutics include Lexeo Therapeutics (LXEO), iTeos Therapeutics (ITOS), Alvotech (ALVO), Adaptive Biotechnologies (ADPT), Replimune Group (REPL), Taysha Gene Therapies (TSHA), Editas Medicine (EDIT), C4 Therapeutics (CCCC), TScan Therapeutics (TCRX), and Voyager Therapeutics (VYGR). These companies are all part of the "biological products, except diagnostic" industry.
Lexeo Therapeutics (NASDAQ:LXEO) and Fate Therapeutics (NASDAQ:FATE) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, community ranking, valuation, analyst recommendations, earnings, media sentiment, profitability, institutional ownership and dividends.
Lexeo Therapeutics has higher earnings, but lower revenue than Fate Therapeutics. Fate Therapeutics is trading at a lower price-to-earnings ratio than Lexeo Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Fate Therapeutics had 21 more articles in the media than Lexeo Therapeutics. MarketBeat recorded 29 mentions for Fate Therapeutics and 8 mentions for Lexeo Therapeutics. Lexeo Therapeutics' average media sentiment score of 0.12 beat Fate Therapeutics' score of 0.08 indicating that Fate Therapeutics is being referred to more favorably in the news media.
Lexeo Therapeutics currently has a consensus price target of $20.80, indicating a potential upside of 57.81%. Fate Therapeutics has a consensus price target of $6.75, indicating a potential upside of 56.25%. Given Fate Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Lexeo Therapeutics is more favorable than Fate Therapeutics.
60.7% of Lexeo Therapeutics shares are held by institutional investors. Comparatively, 97.5% of Fate Therapeutics shares are held by institutional investors. 5.0% of Fate Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Fate Therapeutics received 473 more outperform votes than Lexeo Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Lexeo Therapeutics an outperform vote while only 68.72% of users gave Fate Therapeutics an outperform vote.
Lexeo Therapeutics has a net margin of 0.00% compared to Lexeo Therapeutics' net margin of -2,933.79%. Lexeo Therapeutics' return on equity of -46.49% beat Fate Therapeutics' return on equity.
Summary
Fate Therapeutics beats Lexeo Therapeutics on 9 of the 17 factors compared between the two stocks.
Get Fate Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for FATE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding FATE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Fate Therapeutics Competitors List
Related Companies and Tools
